Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Net Cash Flow (2023 - 2025)

Kura Oncology (KURA) has disclosed Net Cash Flow for 3 consecutive years, with $53.8 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 69.25% to $53.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$75.4 million through Dec 2025, down 140.27% year-over-year, with the annual reading at -$75.4 million for FY2025, 140.27% down from the prior year.
  • Net Cash Flow for Q4 2025 was $53.8 million at Kura Oncology, up from $13.3 million in the prior quarter.
  • The five-year high for Net Cash Flow was $175.0 million in Q4 2024, with the low at -$173.2 million in Q1 2025.
  • Average Net Cash Flow over 3 years is $274083.3, with a median of $4.2 million recorded in 2024.
  • The sharpest move saw Net Cash Flow surged 1939.89% in 2024, then crashed 4235.46% in 2025.
  • Over 3 years, Net Cash Flow stood at $8.6 million in 2023, then soared by 1939.89% to $175.0 million in 2024, then tumbled by 69.25% to $53.8 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $53.8 million, $13.3 million, and $30.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.